Vermillion Corporation

Amunix Pharmaceuticals, Inc

Vermilllion, Inc.

The University of Texas System

Mcgill University

Amunix Operating Inc.

Johns Hopkins University

Ciphergen Biosystems, Inc.

Vladimir Podust

Volker Schellenberger

Kaj Blennow

Bee-Cheng Sim

James Norton McGuire

Huw Alun Davies

Anja Hviid Simonsen

Tai-Tung Yip

Chia-wei Wang

Eric Thomas Fung

Sheng Ding

Bryant McLaughlin

Chen Gu

Fan Yang

Judah M Folkman

Zhen Zhang

Robert C Bast

Daniel W Chan

William E Rich

Chia-Wei Wang

Desiree Thayer

Giannoula Lakka Klement

Jin Song

John Beaber

Zheng Wang

Karin Sundfeldt

Brian Ward

Bjorg Kristjansdottir

Charlotte Clarke

Mats Brannstrom

Momar Ndao

Rebecca Caffrey

Terence William Spithill

Hongshan Li

Regis Perichon

Enrique Dalmasso

Robert Bast

Bryant Mclaughlin

James Mcguire

Kaj Clinical Neurochemistry Laboratory Blennow

The present invention relates to activatable recombinant polypeptide compositions comprising a cleavage release segment. In some instances, the activatable recombinant polypeptide compositions include an XTEN linked to binding moieties by cleavable release segments that, when cleaved, the binding moieties are capable of binding together effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable activatable recombinant compositions.

Release segments and binding compositions comprising same

The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.

XTEN conjugate compositions and methods of making same

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, it has been found that the biomarkers set forth in Table 1 are biomarkers for ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

Biomarkers for ovarian cancer

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry, immunoassay, or other means.

Methods for diagnosing ovarian cancer

The present invention relates to the fields of immunology and biochemistry. Particularly, the present invention describes methods, devices and kits for early detection of clinical conditions having associated changes in systemic angiogenic activity, particularly cancers, inflammatory conditions, infections, and events associated with pregnancy and abortion.

Platelet biomarkers for cancer

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.

Serum biomarkers for Chagas disease

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The biomarkers can be detected by SELDI mass spectrometry.

Saposin D and FAM3C are biomarkers for alzheimer's disease

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

Biomarkers for alzheimer's disease

The present invention provides a neurosecretory protein VGF peptide useful in qualifying Alzheimer's disease status in a patient. In particular, this peptide and modified forms thereof may be used to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The peptide biomarker can be detected by SELDI mass spectrometry.

Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease

Growing community of inventors

Castro Valley, CA, United States of America

Vladimir Podust